Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...

Citigroup started coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $145.00 target ...

German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) ...

Citi analyst Geoff Meacham initiated coverage of BioNTech (BNTX) with a Buy rating and $145 price target Healthcare policy remains a key ...

U.S.-listed shares of BioNTech SE ended Monday nearly 3.2% lower, weighed down by a weak full-year revenue projection even as ...

BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company ...

BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

The mRNA technology behind coronavirus vaccines is now being used to create bespoke vaccines for cancer patients.

In the last three months, 4 analysts have published ratings on BioNTech (NASDAQ:BNTX), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary ...